Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 9/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 9/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 9/20 | 0.48 |
| ▸ | GCGR | P47871 | 1/20 | 0.48 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23407656 | 1.00 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL23407706 | 0.87 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL29620835 | 0.87 | AAK1 (0.46) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL23407698 | 0.87 | AAK1 (0.46) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL23407636 | 0.84 | GRM2 (0.48) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL29620805 | 0.84 | GRM2 (0.48) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL23407565 | 0.84 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL29620813 | 0.83 | TLR9 (0.47) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL23407657 | 0.83 | TLR9 (0.47) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL23407668 | 0.80 | MAPK14 (0.45) | MAPK14MAPK13MAPK12MAPK11GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704105-B9 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD (GB) | 2025-03-05 | — | — | EP | disclosed |
| EP-3704105-B1 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD (GB) | 2024-10-16 | — | — | EP | disclosed |
| US-20220372027-A1 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD. (GB) | 2022-11-24 | — | — | US | disclosed |
| US-11345694-B2 | Antibacterial compounds | DISCUVA LTD. (GB) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345694-B2 | Antibacterial compounds | CFTR, MRPL21, NQO1 | MAPK14 3035/4885MAPK13 3687/4885MAPK12 2492/4885 |
| US-20220372027-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, NRDC, PGLS | MAPK14 2955/4885MAPK13 3493/4885MAPK12 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.